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ABSTRACT

INTRODUCTION

Sudemycin E is an analog of the pre-messenger
RNA splicing modulator FR901464 and its derivative spliceostatin A. Sudemycin E causes the death
of cancer cells through an unknown mechanism.
We found that similar to spliceostatin A,
sudemycin E binds to the U2 small nuclear
ribonucleoprotein (snRNP) component SF3B1.
Native chromatin immunoprecipitations showed
that U2 snRNPs physically interact with nucleosomes. Sudemycin E induces a dissociation of
the U2 snRNPs and decreases their interaction
with nucleosomes. To determine the effect on
gene expression, we performed genome-wide
array analysis. Sudemycin E first causes a rapid
change in alternative
pre-messenger
RNA
splicing, which is later followed by changes in
overall gene expression and arrest in the G2
phase of the cell cycle. The changes in alternative
exon usage correlate with a loss of the H3K36me3
modification in chromatin encoding these exons.
We propose that sudemycin E interferes with the
ability of U2 snRNP to maintain an H3K36me3
modification in actively transcribed genes. Thus,
in addition to the reversible changes in alternative
splicing, sudemycin E causes changes in chromatin modifications that result in chromatin
condensation, which is a likely contributing factor
to cancer cell death.

Almost all human polymerase II transcripts undergo
alternative pre-messenger RNA (pre-mRNA) splicing,
which increases the number of proteins that can be
encoded in the genome. Exons in pre-mRNA are
recognized by the spliceosome, a macromolecular
complex composed of ﬁve small RNAs and at least 170
proteins (1). An exon is deﬁned by its two splice sites and
the branch point, which are only weakly conserved in
mammals. The spliceosome assembles around exons in a
step-wise manner. First, U1 snRNP binds to the 50 splice
site, followed by binding of splicing factor 1 to the branch
point, which increases U2AF binding to the 30 splice site,
stabilizing the entry of U2 snRNP and the release of
splicing factor 1. In this spliceosomal A complex, the
branch point adenosine is recognized by the U2 snRNP
through an interaction between the U2 component
SF3B1/(SAP155) and U2AF (2). This stabilization is
ATP dependent and allows the inclusion of the U4/U5/
U6 snRNPs, leading to the formation of the assembled
spliceosome in the B complex. Further rearrangements
allow the catalysis of the splicing reaction in the C
complex in two transesteriﬁcation reactions (3). The U2
snRNP undergoes structural changes during the splicing
reaction and releases its SF3 complex after the ﬁrst catalytic splicing step (4).
Alternative exon recognition occurs predominantly
cotranscriptional and is therefore mechanistically coupled
to other events in gene expression. For example, a fastmoving RNA polymerase promotes alternative exon
skipping (5,6). There is accumulating evidence that
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chromatin structure is linked to exon selection.
Nucleosomes are associated with DNA sequences that
encode exons (7,8). Histone modiﬁcation, such as
H3K4me3, assists in the recruitment of U2 snRNP components to sites of active transcription, which could promote
exon recognition (9). It is possible that pre-mRNA splicing
affects chromatin changes, in return, as DNA encoding
exons are characterized by the H3K36me3 modiﬁcation.
This modiﬁcation is lower in DNA corresponding to alternative exons, when compared with constitutive exon.
Because on average, alternative exons of the same premRNA assemble fewer spliceosomes than the constitutive
exons, this suggests that the activity of the spliceosome is
reﬂected in the H3K36me3 modiﬁcation.
Reﬂecting the central role of alternative pre-mRNA
splicing in gene expression, abnormal splicing patterns are
frequently associated with human diseases. Deregulated
splicing patterns are a hallmark of cancer, but the
reason for this deregulation is not fully understood
(10–12). The tumor microenvironment is generally
hypoxic and more acidic than normal tissue, which can
result in the pathological generation of protein isoforms
supporting metastasis (13). Several protein isoforms
generated by alternative splicing are crucial for cancer
progression and are the subject of experimental therapeutic intervention. For example, the RON tyrosine
kinase gene can generate a constitutively active kinase
due to the skipping of an alternative exon (14). The
exon, controlled by the splicing factor SF2/ASF, determines the epithelial to mesenchymal transition, which determines the invasiveness of cancer cells (15). Another
hallmark of cancer cells are changes in their chromatin
structure (16). The recent demonstration that chromatin
structure globally inﬂuences the localization and availability of splicing factors (17) indicates that missplicing
observed in cancer could originate in an altered nuclear
structure.
Two naturally occurring compounds, FR901464 and
pladienolide B, have been shown to affect pre-mRNA
splicing in vivo and to suppress tumor growth (18).
FR901464 has been derivatized to generate spliceostatin
A (19), which targets the U2 snRNP component
SF3B, and modulates alternative splicing in vitro (19).
Further analysis has shown that spliceostatin A inhibits spliceosome assembly in the B complex after a
pre-spliceosomal complex has been formed (20).
Spliceostatin A inﬂuences the interaction of SF3B1 with
the pre-mRNA, leading to a nonproductive recruitment of
U2 snRNP, which affects a subset of 30 splice sites (21),
explaining why in vivo spliceostatin A targets certain alternative splicing events.
Sudemycin E is a reﬁned totally synthetic analog of
FR901464 (22). This compound selectively stops the
growth of tumors in mice and preferably targets cancer
cells, sparing nonneoplastic cells. Similar to spliceostatin
A, it changes alternative splicing (23).
Here, we analyzed the effect of sudemycin E on cancer
cells. Sudemycin works via a two-stage mechanism, ﬁrst
reversibly affecting alternative splicing of 7.5% of alternative exons due to a dissociation of U2 snRNPs. Possibly
due to the dissociation, sudemycin E decreases the binding

of U2 snRNPs to nucleosomes. As a likely result, the
H3K36me3 chromatin mark in DNA corresponding to
altered alternative exons is decreased. Several hours
later, we found general changes in gene expression, not
just in alternative splicing. Together, these events lead to
chromatin condensation and an arrest in the G2 stage of
the cell cycle.
MATERIALS AND METHODS
Cell culture
Rh18 cells, established at St. Jude Children’s Research
Hospital (24), were grown in RPMI 1640 medium
(Roswell Park Memorial Institute) supplemented with
10% (v/v) heat-inactivated fetal calf serum at 37 C in
5% CO2. HEK293 cells (Sigma) were grown in high
glucose Dulbecco’s modiﬁed Eagle’s medium containing
10% (v/v) heat-inactivated fetal calf serum, at 37 C in
5% CO2. Human skin primary ﬁbroblasts (GM 00498D,
Coriell Institute) were grown in minimum essential
medium Eagle containing 10% (v/v) heat-inactivated
fetal calf serum, at 37 C in 5% CO2.
Cell viability
Viability
was
tested
by
metabolizing
3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide
(MTT) by mitochondrial dehydrogenases (Sigma):
1 000 000 cells were treated with the compounds at the
times indicated and were subsequently analyzed with
MTT according to the manufacturer’s protocol. The
MTT staining obtained from cells receiving just dimethyl
sulfoxide (DMSO) control were set as 100% signal.
Biotinylation pull down
Streptavidin beads (Life Technologies) were washed three
times with phosphate-buffered saline (PBS) buffer and
then precleared with 10% bovine serum albumin for
30 min at 4 C. The precleared beads were incubated with
25 ml of DMSO or 10 mM biotinylated sudemycin E and
HeLa nuclear (DundeeCellProducts) extract in 2
immunoprecipitation buffer [IP, 10 mM Tris–HCl (pH
7.4), 150 mM NaCl, 10 mM KCl] overnight. The next
day, beads were separated from unbound fractions,
washed two times and mixed with 90 ml of 1 sodium
dodecyl sulphate (SDS) sample (50 mM Tris–HCl, pH
6.8, 2% SDS, 10% glycerol, 1% b-mercaptoethanol,
12.5 mM ethylenediaminetetraacetic acid and 0.02%
bromophenol blue) buffer. Sixty microliters of unbound
and washed fractions were mixed with 30 ml of 3 SDS
sample buffer. All fractions were boiled for 5 min and
loaded onto 10% SDS–polyacrylamide gels.
Nucleosome preparation
HEK293 cells were pelleted at 1000 rpm at 4 C and washed
in ice-cold PBS buffer. The cell pellet was resuspended in
ice-cold NP-40 lysis buffer [10 mM Tris (pH 7.4), 10 mM
NaCl, 3 mM MgCl2, 0.5% NP-40, 0.15 mM spermine and
0.5 mM spermidine] and incubated on ice for 5 min. The
solution was centrifuged at 3000 rpm for 10 min. The
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nuclear fraction (pellet) was then resuspended in 1 ml of icecold micrococcal nuclease digestion buffer [10 mM Tris (pH
7.4), 15 mM NaCl, 60 mM KCl, 0.15 mM spermine,
0.5 mM spermidine and 1 mM CaCl2] and digested with
50 U/ml micrococcal nuclease at 37 C for 12 min. The
reaction was stopped by addition of EDTA and NP-40 to
an end concentration of 0.01 M and 0.1%, respectively.

loaded onto 10% SDS–polyacrylamide gels. Anti SF3B1
antisera was obtained from Abcam. To estimate the
Svedberg (S) values, we used conalbumin (molecular
weight 75 000 D; 5.4 S), aldolase (15 800 D, 11.5 S) and
ferritin (440 000, 17 S), all from GE healthcare.
Nucleosome immunoprecipitation

Sudemycin E was dissolved in DMSO at 10 mM ﬁnal concentration. Rh18, HEK293 and ﬁbroblasts were plated
and cultured for 24 h to 80% conﬂuence before sudemycin
E treatment. The cells were treated with 1 or 10 mM
sudemycins (up to 48 h) or vehicle (DMSO) equal to
solvent.

Nucleosomes were immunoprecipitated in 2 IP buffer
[10 mM Tris–HCl (pH 7.4), 150 mM NaCl, 10 mM KCl]
for 14–16 h at 4 C using speciﬁc antibodies to H3
(AbCam) or no antibody (No Ab). The following day,
beads were separated from unbound fractions and washed
several times. The unbound (Input), H3 and No Ab fractions
were collected, mixed with 3 SDS sample buffer, boiled for
5 min and loaded onto 10% SDS–polyacrylamide gels.

Determination of sudemycin E concentration

Chromatin immunoprecipitations

After sudemycin E addition to the medium, the medium
and cells were collected and extracted with acetonitrile.
The extracted solution was analyzed by ultra-performance
liquid mass spectrometry coupled to mass spectrometry
[UPLC-MS/MS (TQ detector)]. The parent ion of
sudemycin E was quantitatively determined by comparing
it with a standard curve.

Rh18 and HEK293 cells were lysed and sheared by sonication in 0.1% NP-40 in PBS (Sigma) lysis buffer to generate
cellular chromatin fragments of 400–500 bp. The chromatin was immunoprecipitated for 14–16 h at 4 C using
speciﬁc antibodies to H3K36me3 and H3K27me3
(AbCam). After the incubation, chromatin immunoprecipitates were puriﬁed and then 2 ml of each sample was
analyzed by real-time polymerase chain reaction (PCR).

Sudemycin E handling

Flow cytometry
In all, 1  106 HEK293 cells were ﬁxed in 70% ethanol,
incubated for 30 min at 4 C, treated with RNase A
(250 mg/ml) and stained with propidium iodide 10 mg/ml
(Sigma) for 30 min at 37 C. Cell cycle analysis was
performed on a ﬂow cytometer (FACSCalibur, BD
Biosciences).
Microscopy
HEK293 cells were seeded into 4-well chambers (Thermo
Scientiﬁc). After 24 h, cells were treated with 0, 4, 6 and
24 h with sudemycin E and then washed with PBS. Four
percent of paraformaldehyde in PBS, pH 7.4, was used for
10 min to ﬁx cells. Then, the cells were incubated for
10 min with PBS containing 0.25% Triton X-100
(PBST). One percent bovine serum albumin in PBST
was used to block unspeciﬁc antibody binding. Cells
were incubated for 1 h in SF3B1 antibody, washed three
times with PBS and then incubated for another hour with
ﬂuorescein isothiocyanate (FITC) anti-rabbit antibody.
Finally, cells were stained with 4’,6-diamidino-2phenylindole (DAPI) and analyzed by confocal microscopy (Nikon A1R-A1 Confocal Microscope System).
Glycerol gradient analysis
Nuclear extract from HeLa cells was loaded onto a linear
4-ml 15–30% glycerol gradient prepared in G150 buffer
(20 mM HEPES, pH 7.9, 150 mM NaCl, 1.5 mM MgCl2,
0.5 mM dithioerythritol). After centrifugation in a
Beckman SW60Ti rotor at 35 000 rpm (corresponding to
165 000g), at 4 C for 15 h, the gradient was fractionated
into 26 fractions of 150 ml each. 30 ml of 3 SDS sample
buffer were added to 60 ml of each fraction. The samples
were boiled for 5 min, and 15 ml of each fraction was

Real-time PCR
The real-time PCR was carried out in the Strategene
Mx3005P (Agilent Technologies), using SYBR green
reagent (Life Technologies). The relative expression was
estimated as follows: 2Ct(reference)  Ct(sample), where Ct (reference) and Ct (sample) were input DNA and speciﬁc histone
modiﬁcation chromatin, respectively. For each experiment, at
least three immunoprecipitations were analyzed.
Reverse transcriptase-polymerase chain reaction
Total RNA from Rh18, HEK293 and ﬁbroblast cells was
extracted using GenElute Mammalian Total RNA
Miniprep kit (Sigma) according to the manufacturer’s instructions. cDNAs were synthesized from 1 mg of each
RNA using SuperScriptÕ III Reverse Transcriptase (Life
Technologies). Reverse transcriptase-polymerase chain
reaction (RT-PCR) experiments were carried out using
1 ml of each cDNA as template and speciﬁc primers.
Products were visualized on gel electrophoresis after
ethidium bromide staining. Primers used were as follows:
RPp30 _FOR:GAGGCCTGGCTTTTGAACTT;
RPp30 _REV:CCTTGGCGTCACTTTCAGAG;
DUSP11_FOR:GACATCAAGTGCCTGATGATGA;
DUSP11_REV:ATGTCCCCGGCACCTATT;
SRRM1_FOR:GACTCTGGCTCCTCCTCCTC;
SRRM1_REV:GGACTTCTCCTCCGTCTACCA;
PAPOLG_FOR:AAGAGATCCCATTCCCCATC;
PAPOLG_REV:TGCGTGATGTATCAATAGTTGGA;
MLH3_FOR:TTATTGCCTGTTTGATGAGCAC;
MLH3_REV:TCCTTTGTTCCTCTGTCACTGTT;
ß-ACTIN_FOR:AGAGCTACGAGCTGCCTGAC;
ß-ACTIN_REV:GGATGTCCACGTCACACTTC;
ADAT1_FOR:ATGGCCAGGTGGTCTTCATA;
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ADAT1_REV:GTCACTTGCACCGGCTTATC;
DNAJB7_FOR:CAGCAACAGAGATCCCCCTA;
DNAJB7_REV:AGCACCAACTGTCACCACAA;
PRPF39_FOR:ACCCTGGTGATCCTGAGACA;
PRPF39_REV:GAAGCTAATTCCCTTCGCAAC;
cRPP30 _FOR:TATATCTAGTGCTGCAGAAAGG;
cRPP30 _REV:GCCTAAAGAAAGTGGGGATAA;
cDUSP11_FOR:TTGTTTTGTTATTTAGGTTGGA;
cDUSP11_REV:ACTCACTCCTATAATACCAACACTT;
cSRRM1_FOR:ATCGCCAGTGACTAAAAG;
cSRRM1_REV:AATCTAAGTTCAAATAAGGGTC;
cPAPOLG_FOR:CTGCCTACATAGGCCTATCGA;
cPAPOLG_REV:GCGAGAGTCGTCTCTTAGAT;
cMLH3_FOR:CTGGGATTCAAACATATGGGATA;
cMLH3_REV:TCCAGACGTATACGCTCAT;
cADAT1_FOR:TATTTTGGGAGGTTGAGG;
cADAT1_REV:ATCAAAAAATTTTTTAAAATAAAATCT;
cDNAJB7_FOR:GTGTAATGTTTATTATTTTGTTTGAGA;
cDNAJB7_REV:ATTCAAACGATTCTCCTATCTC;
cPRPF39_FOR:GATTTTTGGGAGGGTTAGG;
cPRPF39_REV:CCTAACCGAAAATAACACTTCA;
AURKB_sFOR:ATGACCGGAGGAGGATCTAC;
AURKB_sREV:GATGGACCTCCAGCTACAAG;
AURKB_FOR:ACATCTTAACGCGGCACTTC;
AURKB_REV:TTGTCTTCCTCCTCAGGGAGG.
Array analysis
RNA was isolated using Qiagen kits. Its quality was
determined by RNA integrity number analysis, and
samples with an RNA integrity number > 9.5 were used
following the Affymetrix labeling procedure.
For the analysis, the signal from Affymetrix human
junction arrays (HJAY) was normalized using the ‘Probe
scaling’ method. The background was corrected with
ProbeEffect from GeneBase (25). The gene expression
index was computed from probes that were selected using
ProbeSelect from GeneBase (25). The gene expression
signals were computed using these probes. Genes were considered expressed if the mean intensity was 500. Genes
were considered regulated if (i) they were expressed in at
least one condition (i.e. VPA and/or control); (ii) the foldchange was 1.5, which is above the noise level seen in cells
(26); and (iii) the unpaired t-test P-value between gene
intensities was 0.05. For each probe, a splicing index
was computed. Unpaired t-tests were performed to determine the difference in probe expression between the two
samples as described previously (27). Probe P-values in
each probeset were then summarized using Fisher’s
method. Using annotation ﬁles, splicing patterns (cassette
exons, 50 /30 alternative splice sites and mutually exclusive
exons) were tested for a difference between isoforms, selecting the ones with a minimum number of regulated probeset
(with a P  0.01) in each competing isoform (at least onethird of ‘exclusion’ probesets have to be signiﬁcant; at least
one-third of ‘inclusion’ probesets have to be signiﬁcant and
show an opposite regulation for the splicing index
compared with the ‘exclusion’ probesets). For example,
for a single cassette exon, the exclusion junction and at
least one of the three inclusion probesets (one exon
probeset and two inclusion junction probesets) have to be

signiﬁcant and have to show an opposite regulation for the
splicing index. The exon junction arrays contained 13 150
alternative cassette exons, 6517 alternative 50 /30 exons and
1145 mutually exclusive exons (20 812 alternative exons). A
total of 33 395 genes are taken into account.
RESULTS
Sudemycin E binds to SF3B1 and is toxic for some
cancer cells
Sudemycin E (Figure 1A, left) is chemically related to
spliceostatin A, a methylated derivative of FR901464,
which is a natural product that binds to the U2 component
SF3B1 and modulates splicing (19). Sudemycin E is a more
stable chemically reﬁned totally synthetic analog of
FR901464 and its derivative spliceostatin A, which is
much more chemically stable than these compounds (22).
Sudemycin E also has much less stereochemical complexity
than FR901464 or spliceostatin A, as it contains only three
stereocenters compared with nine in those compounds (22).
This means that sudemycin E and analogs are more
amenable to medicinal chemistry structure-activity studies
and scale-up to large quantities that will ultimately be
needed for possible future clinical studies. Sudemycin
E selectively stops the growth of tumors in mice and
preferably targets cancer cells, sparing nonneoplastic cells.
Similar to spliceostatin A, it changes alternative splicing
(23).
We ﬁrst tested whether sudemycin E also binds
to SF3B1 and used a biotinylated derivative of sudemycin
in pull-down experiments. After binding biotinylated
sudemycin (Figure 1A, right) to streptavidin-coated
magnetic beads, the beads were incubated with HeLa
nuclear extract, washed and protein was eluted. Using
western blot, we detected binding of SF3B1 to sudemycin
E-coated beads. This demonstrates sudemycin binding to
SF3B1, as expected from its chemical structure.
Sudemycin E causes the death of certain cancer
cells, while being generally nontoxic in nontransformed
cells (23). To understand the selectivity for cancer cells,
we determined the IC50 of sudemycin E toxicity in four
cell lines: Rh18, a rhabdomyosarcoma cell line representing the most common soft tissue sarcoma in children;
HEK293 cells, adenovirus-transformed human embryonic
kidney cells; HeLa cells, a cervical cancer cell line; and
human primary skin ﬁbroblasts. After sudemycin
E treatment, death of cells becomes noticeable at 24 h
and is more pronounced at 48 h, where we determined
the IC50 using the MTT assay. As shown in Figure 1C,
the IC50 ranges from 0.16 to >30 mM. HeLa cells are most
sensitive to sudemycin E, with an IC50 160 nM after 48 h
of treatment, followed by Rh18 cells with an IC50 of
1.12 mM. In contrast, HEK293 cells and primary ﬁbroblasts are 10–30 times less sensitive to sudemycin
E, reﬂecting the selectivity of the drug for cancer cells.
A short incubation with sudemycin E is sufﬁcient to cause
cell death
The IC50 in Rh18 cells depends on the time the drug is
present in the cells and ranges from >30, 5 and 0.8 mM
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Figure 1. Sudemycin E binds to SF3B1 and is toxic for cancer cell lines. (A) Structure of sudemycin E (left) and its biotinylated derivative (right).
(B) Binding of biotinylated sudemycin to SF3B1. Biotinylated sudemycin was bound to streptavidin coupled to magnetic beads, and incubated with
HeLa nuclear extract, followed by washing with PBS. The bound SF3B was eluted by boiling with 1% SDS, 10 mM Tris and SF3B1 detected by
western blot. L: load, W: wash, B: bound sudemycin. Load corresponds to the total input. Ten percent of the input was loaded. (C) IC50 determined
for Rh18, HEK293, HeLa and primary ﬁbroblast cells using the MTT assay; n = 4. Sude E: sudemycin E.

after 2, 8 and 72 h of treatment, respectively (23).
Therefore, we asked whether cells have to be continuously
exposed to sudemycin E for a cytotoxic effect to occur or
whether the drug triggers a cellular response that causes
the death of cells.
Rh18 cells were treated with 1 mM sudemycin, which
was washed out by changing the cell culture medium
after 30 min. This was followed by 48 h culture without
the drug (Figure 2A). The survival of these cells was
compared with cells treated with 1 mM sudemycin for
48 h, where we left sudemycin E on the cells (Figure 2B).
We did not observe signiﬁcant differences in cell viability,
measured by the MTT assay between the two conditions.
Using mass spectrometry, we determined sudemycin E
concentration in medium and found that it rapidly disappears (Figure 2C and D).
The natural compound FR901463 that provided the
scaffold for sudemycin E was shown to arrest M-8 cells in
the G2/M phase of the cell cycle (18). Therefore, we asked
whether we observe similar effects after short sudemycin E
incubation times. We performed cell cycle analysis after
cells were treated for 24 h with sudemycin E or treated for
only 30 min, followed by a medium change that removes
sudemycin and a subsequent incubation for 23.5 h.
Sudemycin E was used at a concentration corresponding
to the IC50, 1 mM for Rh18 cells and 10 mM for HEK293
cells (Figure 2E and F). In addition, a 1 mM concentration
that shows low toxicity for HEK293 cells was used and had
no signiﬁcant effect on the cell cycle (Figure 2G).

As shown in Figure 2E and F, when used at concentrations that are toxic for cells, we observed an arrest of both
Rh18 and HEK293 cells in G2. When used for 24 h, the
amount of cells in G2 increased 3-fold. When used for
only 30 min, we found an increase of 50% in both cell
lines, which was statistically signiﬁcant (Figure 2E and F).
In contrast, using 1 mM sudemycin, a concentration that is
not cytotoxic for HEK293 cells did not cause signiﬁcant
changes (Figure 2G). The data indicate that sudemycin E
causes an arrest of cells in the G2 phase of the cell cycle,
which can also be seen after a 30-min incubation time.
Together, the data show that sudemycin has cytotoxic
effects after a short incubation time, and that it triggers
events that cause later cell death, as opposed to continuous blocking a cell activity that is needed for survival.
Sudemycin E breaks up the U2 complex in vitro
SF3B1 is part of the U2 complex, a macromolecular
complex of at least 11 proteins assembling on the small U2
RNA (SM proteins, SF3B130, SF3B155, SF3a60, SF3B145,
SF3a120, SF3a66, U2-A’, U2-B’, SFb49, SF3B14b and
SF3B10). The U2 complex is largely remodeled during the
splicing reaction, with the loss of SF3A and SF3B proteins
during splicing catalysis (28). Therefore, we determine the
inﬂuence of sudemycin E on the U2 complex using HeLa
nuclear extract. HeLa nuclear extract was incubated with
10 mM sudemycin and separated on glycerol gradients, as
previously described (29). As shown in Figure 3A, after
treatment, we detect SF3B1 no longer in the U2 complex
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of about 17 S, but in lighter fractions, corresponding to 11–
12 S. U2 snRNPs extracted under high salt conditions
sediment at 12 S, as several proteins present under splicing
conditions are lost from the U2 snRNP (29).
This suggests that sudemycin E does not simply bind to
SF3B1 found in the U2 complex, but causes its dissociation. Other than in the loaded sample, there was no
sudemycin E present in the gradient, suggesting that the
effect of sudemycin on the U2 complex is irreversible.
SF3B1 physically interacts with histone H3
It is well established that splicing and transcription are
coupled (30). Deep sequencing experiments indicate an
association of U2 snRNPs with histone H3 (31).
Therefore, we tested whether histone H3 can physically
interact with components of the U2 complex.

Because chromatin is largely insoluble, we puriﬁed
oligo-nucleosomes from sudemycin-treated and naı̈ve
Hela cells by performing limited chromatin nuclease digestion (Figure 4A). Mono- and dinucleosomes were
immunoprecipitated with an anti H3 antiserum, and
bound SF3B1 was detected using western blot. As
shown in Figure 4B and C, we observe coprecipitation
between the U2 complex SF3B1 and nucleosomes,
demonstrating a physical interaction. Importantly, in the
presence of sudemycin E, this interaction is reduced by
25% (P < 0.05, n = 4).
These data indicate a physical interaction between
nucleosomes and SF3B1. It is likely that SF3B1 is in a
complex with U2 that is bound by nucleosomes. The reduction of SF3B1 binding to nucleosomes could be caused
by a dissociation of the U2 complex that we observed in
gradient centrifugation.
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A 6-h treatment with sudemycin E predominantly changes
alternative splicing
To determine the molecular effects of sudemycin treatment, we performed genome-wide exon junction array
analysis. First, we treated Rh18 cells with 1 mM of
sudemycin E for 6 h. The concentration of 1 mM was
chosen because it is in the IC50 range for Rh18 cells,
which is 1.12 ± 0.05 mM (Figure 1C). We choose 6 h, as
there is no measurable cell death at this time point, which
allows detecting early consequences of sudemycin E
action. The array analysis indicated that sudemycin E

changes 1553 alternative exons (Figure 5B), which is
expected for a substance inhibiting the U2 snRNP.
Unexpectedly, we observed changes in general gene expression for 575 genes (Figure 5A). Gene ontology (GO)
pathways that were affected the strongest were nitrogen
metabolic processes, nitrogen compound processes and
nucleoside synthesis. Because there is no observable cell
death at 6 h of treatment (Figure 2A and B), it is likely
that the changes observed here represent the ﬁrst cellular
response to sudemycin, which affects alternative exons in
most biological pathways. These data are in agreement
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with ﬁndings for spliceostatin (21) that rapidly changes
splice site selection of selected alternative exons.
A 24-h treatment with sudemycin E changes
predominantly gene expression
To determine the changes in gene expression under conditions when Rh18 cells start dying due to sudemycin E
treatment, we added 10 mM of the drug for 24 h. Because
sudemycin E rapidly disappears in the presence of Rh18
cells (Figure 2C and D), we choose a higher sudemycin E
concentration to ensure that sudemycin E is present
throughout the treatment time. Unexpectedly, we
observed more changes in overall gene expression (3777;
Figure 5C) than in alternative splicing (2117; Figure 5D).
The most affected Kyoto Encyclopedia of Genes and
Genomes pathway was the spliceosome, where 43 of
128 genes were affected. Forty-one of these genes were
upregulated. About 4% of all changes affected genes
acting in DNA metabolism, indicating a deregulation in
DNA repair and replication. Most of these genes (2108)
were upregulated in expression; 1669 were downregulated.
The data sets obtained after 6 and 10 h of sudemycin E
treatment are mostly not overlapping. The most striking
difference is a change in expression of 43 of 128 genes

acting in the spliceosome, none of which was changed
after 6 h of treatment.
Together, the data suggest that sudemycin E acts in two
stages: ﬁrst, it causes changes in alternative splicing. Later,
the drug changes mainly gene expression, which affects the
spliceosome and DNA metabolism the strongest.
Early changes in alternative splicing occur gradually and
are reversible
We next validated changes observed in the arrays by RTPCR, using primers in constitutive exons ﬂanking an
alternative cassette exon. The overall validation rate was
>85% (7 of 8), when splicing events with a high conﬁdence of prediction were used (P < 1010).
Because sudemycin E appears to act in a step-wise
manner, we determined changes in alternative splicing in
a time course by RT-PCR. We ﬁrst analyzed Rh18 cells
using 1 mM sudemycin, a concentration around the IC50
value. Sudemycin E was added at time 0, and cells were
tested after 2–24 h, without changing the medium. For the
genes tested, changes in alternative splicing increased
gradually for 6 h and reverted to the original splicing
pattern after 24 h (Figure 6A), consistent with the
decrease of sudemycin E (Figure 2D).
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We next used the same 1 mM sudemycin E concentration
for HEK293 cells and did not observe signiﬁcant changes
in alternative splicing (Figure 6B). However, when using
the higher concentration of 10 mM, which is comparable
with the IC50 of sudemycin E in HEK293 cells, we
observed changes in alternative splicing (Figure 6C),
similar to the ones observed in Rh18 cells. In all concentrations and cell used, the alternative splicing patterns
revert to the original condition after 24 h. This could
be due to the loss of sudemycin, as we found that >90%
of sudemycin E is degraded after 12 h in cell culture
(Figure 2D).
The data indicate that sudemycin E rapidly changes
splicing, as expected for a compound interfering with the
U2 component SF3B1. These changes do not persist in
cells, most likely because sudemycin E decays and cells
repair the damaged U2 particles.
Thirty minutes of sudemycin E treatment cause
changes in alternative splicing
Because sudemycin E caused death of cells 48 h after a
short incubation time (Figure 2A), we investigated
whether 30 min of sudemycin E treatment causes

changes in alternative splicing. Rh18 cells were treated
with 1 mM sudemycin E for 30 min. The drug was then
removed by a change in medium. Changes in splicing
were determined after 6 h by RT-PCR. As shown in
Figure 7, this short pulse is sufﬁcient to trigger a change
in alternative splicing. This indicates that sudemycin
causes rapid changes in cells, leading to detectable
changes in alternative splicing later. Changes in alternative
splicing are most likely detected after enough of the
mRNA present before drug treatment decayed, which
results in their detection after a few hours.
Changes in gene expression caused by sudemycin
E persist after drug treatment
An unexpected ﬁnding of sudemycin E treatment was the
deregulation of general gene expression (validation rate by
RT-PCR 60%, 8 of 13). We analyzed several of these
changes in detailed time courses using RT-PCR. As
shown in Figure 8A, in Rh18 cells treated with 1 mM
sudemycin, gene expression changes gradually over time,
similar to changes in alternative splicing. However, most
of the changes in expression do not revert to the original
splicing pattern when sudemycin E is degraded after 24 h
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(Figure 2C). Similar to changes in splicing, most analyzed
genes in HEK293 cells are not changed using 1 mM
sudemycin E (Figure 8B). However, HEK293 cells change
splicing patterns in response to sudemycin E at a concentration of 10 mM, near their particular IC50, similar to Rh18
cells (Figure 8C and B). These data suggest that changes in
gene expression evoked by sudemycin E are generally not as
rapidly reversible as changes in alternative splicing.
Sudemycin E changes histone modiﬁcations
The persistent change in gene expression after sudemycin
E treatment suggested a change in chromatin modiﬁcation. It has been shown that U2 snRNPs associate with
H3K36me3 modiﬁcations (31) and we could detect
binding of the U2 component SF3B1 to nucleosomes, supporting the idea that U2 directly interacts with chromatin.
Furthermore, sudemycin E decreases SF3B1 binding
(Figure 4C). This indicates that sudemycin E

treatment changes the U2/nucleosome interaction,
possibly because the drug causes a dissociation of the
U2 complex (Figure 3).
We tested an inﬂuence of sudemycin E on histone modiﬁcations using chromatin immunoprecipitations. Cells
were treated with sudemycin E for 6 h, and chromatin
was immunoprecipitated using an H3K36me3 antibody.
We then measured the DNA corresponding to premRNA intron/exon borders that are inﬂuenced by alternative splicing using real-time PCR. As shown in
Figure 9A and B, we found a marked decrease of
H3K36me3 in both Rh18 and HEK293 cells when
regions within the gene were analyzed. Similar to other
experiments, we used 1 mM sudemycin E for Rh18 cells
and 10 mM for HEK293 cells. Beta-actin as a nonaffected
gene showed no effect.
Because we detected changes in the overall gene expression after sudemycin E treatment, we analyzed histone
modiﬁcations in promoter regions. We focused on the
H3K27me3 modiﬁcations, which generally represses gene
expression (32). As shown in Figure 9C and D, after 6 h
of sudemycin E treatment, there is an increase in the
H3K27me3 modiﬁcation. This correlates with the decrease
in the overall gene expression that we observed using RTPCR. However, the changes in the promoter regions are not
as uniformly strong as changes in the H3K36me3 modiﬁcations seen at exon junctions. Again, the nonregulated gene
beta actin showed no change in modiﬁcation.
Collectively, the data indicate that sudemycin E causes
a change in chromatin modiﬁcations. The drug decreases modiﬁcations that favor an open chromatin
conformation.
Sudemycin E causes chromatin condensation
H3K36 trimethylation increases transcription and generally
opens chromatin. Because we observed a strong decrease of
H3K36me3 modiﬁcation in target genes after sudemycin E
treatment, we asked whether sudemycin E causes chromatin
condensation. We stained Rh18 cells after 6 and 24 h of
sudemycin E treatment. Similar to spliceostatin A,
sudemycin E disrupts SF3B1-containing speckles. In
addition, we found that treated cells showed an increase of
DAPI staining in large foci (Figure 10), suggestive of chromatin condensation.
DISCUSSION
Splicing modulators related to FR901464 show promise as
anti-cancer drugs. However, the reason for their selectivity
is not understood. Here we investigate the mechanism of sudemycin E, a simple chemical derivative of
FR901464 and its related compound spliceostatin A.
Sudemycin analogs are less complex (containing only
three stereocenters rather than the nine in FR901464
and spliceostatin A), which facilitates its synthesis and
structure–activity relationship analysis. Importantly,
sudemycin E is more potent in killing cancer cells and
tumors than in its toxicity toward normal human
cells (22). FR901464 is chemically unstable in aqueous
solution, with a half-life of 45 min in cell culture medium
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(19). This raises the question whether the change in alternative splicing observed for spliceostatin A (21) is the sole
or the major cause for the death of cancer cells.
Our results suggest that ongoing pre-mRNA splicing is
necessary to keep the epigenetic state of cancer cells.
Sudemycin causes structural changes of U2 snRNPs,
which likely result in epigenetic changes. We propose
that these epigenetic changes strongly contribute to the
selectivity of sudemycin for cancer cells (Figure 11).
Sudemycin E changes alternative splicing
To determine molecular targets of sudemycin E, we performed genome wide array analysis. We found that after
6 h of treatment, 1553 alternative exons are changed,
which represent 7.46% of the alternative exon on the
array. In agreement with studies using reporter genes
(23), this clearly shows that sudemycin E does not
globally block pre-mRNA splicing, but predominantly
modulates a subset of alternative splicing events. This
modulation of alternative splicing, but not a global inhibition in cell culture, has also been reported for
spliceostatin A (21). We did not detect statistical signiﬁcant changes in sequence or exon length in the exons
affected by sudemycin E, but it is likely that similar to
spliceostatin A (21), alternative exons that show suboptimal base pairing to U2 snRNA are affected.
Using identiﬁed splicing events, we compared different
cell lines in their response to sudemycin E. Surprisingly,
we found that the splicing patterns are inﬂuenced in a
similar way independently of sudemycin’s toxicity for
the cell. The only difference is the concentration of
sudemycin E needed to change splicing, which needs to
be higher in sudemycin-insensitive cells to alter splice
site selection. This suggests that sudemycin can enter
both sensitive and insensitive cells.

We followed the effect of sudemycin E on alternative
splicing in time course experiments and observed for most
genes that the strongest changes occur between 2 and 4 h.
Unexpectedly, the splicing patterns revert to the original
mode after 24 h, when we can measure an arrest in cell
cycle. We observed the loss of most of sudemycin E after
24 h of incubation in cells, which could be due to a cellular
degradation system or chemical reactivity of sudemycin E.
Therefore, it is likely that sudemycin E reversibly inhibits
the spliceosome in cells, which will function normally after
the drug has been removed.
Unexpectedly, a 30-min incubation of sudemycin,
followed by drug removal, is enough to obtain a change
in alternative splicing after 6 h and an arrest in the cell
cycle after 24 h. The 6-h time delay could reﬂect the time
it takes to degrade mRNAs present at the time of
sudemycin E treatment, as only after these RNAs are
removed, changes in alternative pre-mRNA splicing will
be visible. The exact molecular mechanism and the
kinetics of sudemycin E action on U2 snRNP remain to
be determined. It is possible that sudemycin E inhibits the
biological activity of SF3B1 before it leads to the dissociation of the U2 complex. The U2 snRNP undergoes rearrangements during the splicing reaction, and it is thus
possible that the binding site for sudemycin E changes
during the reaction. Because only a subset of alternative
exons is affected by sudemycin E, it is likely that
sudemycin E affects only U2 snRNPs that are actively
engaged in the splicing reaction of these exons. U2
complexes participating in splicing of other exons could
be more stable due to other proteins present in exon
enhancer complexes.
Finally, when sudemycin is removed after a 30-min
pulse, the alternative splicing patterns revert to the
original splicing mode. Because the cells still die, it is
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likely that factors other than the splicing changes contribute to cell death.
Sudemycin E causes a dissociation of the U2 complex
in vitro and inﬂuences U2 nucleosome interaction
FR901464 binds to the spliceosomal component SF3B1
(19). SF3B1 is part of the U2 complex, formed by
the association of at least 18 proteins with the U2
snRNA. The SF3 complex composed of SF3B and
SF3A dissociates before the ﬁrst step of splicing, after
the spliceosome has been properly assembled on the premRNA (4).
We found that a biotinylated sudemycin derivative
binds to SF3B1, which was expected due to its pharmacophore similarity to spliceostatin A. Because the U2 snRNP
dissociates during the splicing reaction, we tested the inﬂuence of sudemycin E on the U2 snRNP complex in vitro,
and found that after sudemycin treatment, SF3B1
immunoreactivity is present in lighter gradient fractions,
indicating a dissociation of the U2 complex. When

spliceosomes are prepared under higher salt conditions,
several proteins are stripped off the mature U2 snRNP,
resulting in a particle sedimenting around 12 S (29). After
6 h of sudemycin treatment, we detect SF3B1 in fractions
corresponding to 11–12 S. It remains to be determined
whether sudemycin E has the same effect on U2 snRNPs
as high salt. Isolated SF3B1 protein is expected to
sediment around 11 S assuming a globular structure, but
it is not clear what structure the protein has when
sudemycin E is bound.
The composition of the U2 snRNP complexes formed
after sudemycin E treatment remains to be determined,
but it is possible that the drug recapitulates the natural
dissociation of the SF3 complex from the U2 snRNP that
occurs during the splicing reaction.
The majority, an estimated 80%, of pre-mRNA splicing
occurs co-transcriptionally in human cells (33). It is well
established that chromatin modiﬁcations inﬂuence constitutive and alternative pre-mRNA splicing (5). For
example, exons correspond to speciﬁc chromatin marks
(8,34) and histone modiﬁcations inﬂuence alternative
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splicing by recruiting auxiliary factors to the nascent premRNA (35). In return, RNA guides enzymes to chromatin
modifying complexes (36). To test an interaction between
SF3B1 and chromatin, we prepared soluble mono-, diand tri-nucleosomes under native conditions and
determined SF3B1 binding. We detected SF3B1 after
immunoprecipitations of these preparations, suggesting
an interaction between the U2 snRNPs and nucleosomes.
Because the preparations contain DNA and RNA, it is
possible that they are nucleic acid mediated.
Importantly, sudemycin-treated cells show signiﬁcantly
less binding of SF3B1 to nucleosomes. Together with
our ﬁnding that sudemycin E causes a dissociation of
U2 snRNP, these data indicate that the intact U2
snRNP preferentially binds to nucleosomes.
A functional inﬂuence of sudemycin E on U2 snRNP–
nucleosome interaction was apparent in chromatin

immunoprecipitations using K36me3-modiﬁed histone
H3. It has been earlier shown that the presence of
SF3B3 inﬂuences this mark, which is increased at exon/
intron junctions (31,37). In all genes tested, we found a
decrease in the H3K36me3 modiﬁcation after cells were
treated with sudemycin E at a concentration that causes
cell cycle arrest. H3K36me3 is associated with open chromatin in the bodies of active genes. We postulate that U2
snRNPs participate in maintaining the H3K36me3 modiﬁcation, possibly by direct interaction with nucleosomes in
active genes (Figure 11A). The loss of U2 snRNP activity
caused by sudemycin leads rapidly to a change in alternative splicing (Figure 11B), which is reversed after the drug
is either removed or degraded. Sudemycin E causes a dissociation of U2 snRNP, which likely inﬂuences chromatin
modiﬁcations, such as H3K36me3, which decreases.
Because H3K36me3 is generally associated with open
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causes cell death in these diseases and most investigations
focused on a change in splicing isoforms. Our data suggest
the possibility that changes in pre-mRNA processing
could lead to chromatin changes that ultimately cause
cell death.
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